Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Absorbing Debate: Boston Sci, Abbott Differ On Whether The Future Of Stents Is To Disappear

Executive Summary

Competing visions of the future of percutaneous coronary interventions were on display at TCT year, with Boston Scientific pushing its Synergy bioabsorbable polymer-coated, drug-eluting metal stent platform as the better long-term option to fully-resorbable scaffolds of the type Abbott is first out of the gate with.

You may also be interested in...



Expert Webinar Explores Pressing Questions About Biosorbable Stent Technology

Boston Scientific and inVentive Health recently sponsored a webinar with four internationally well-known experts on coronary stent technology to discuss the pros and cons of new bioabsorbable polymer stent technologies – both the fully resorbable stents and metal drug-eluting stents with a bioresorbable polymer. Here's a summary of the discussion. Medtech Insight is also providing a complete transcript of the event.

Diagnostics A Bright Spot In Lackluster US Interventional Cardiology Market

The US Market for interventional cardiology products, which includes diagnostic and therapeutic products, is anticipated to expand from an estimated $3.3 billion in 2015 to roughly $3.6 billion in total product sales by the year 2020. One bright spot in this otherwise lackluster market is the interventional diagnostic products segment, which is projected to grow at CAGR of 4.7% and reach almost $1 billion by 2020, according to a report by Medtech Insight.

Despite Panel Thumbs-Up, Analysts Downplay Absorb Market Impact

While a panel of FDA experts almost unanimously voted to recommend Abbott's fully bioabsorbable Absorb scaffold, analysts say the stent is unlikely to take significant market share, at least in its current form.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT035957

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel